Activity of alpha-interferons in chronic myelogenous leukaemia

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.

Leukemia·2016

Chronic Myeloid Leukemia: Current Guidelines for Diagnosis and Management.

Hematology (Amsterdam, Netherlands)·2016

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.

Blood cancer journal·2015

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

The New England journal of medicine·2013

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.

Leukemia·2012

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

Leukemia·2012

Treatment of dyslipidaemias with fluvastatin.

British journal of clinical practice. Supplement·2009

Lipoprotein(a) as a marker for coronary heart disease.

British journal of clinical practice. Supplement·2009

Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial.

British journal of clinical practice. Supplement·2009

Risk factor management: the cardiologist's perspective.

British journal of clinical practice. Supplement·2009

Fluvastatin in combination with other lipid-lowering agents.

British journal of clinical practice. Supplement·2009

The patient at risk: who should we be treating?

British journal of clinical practice. Supplement·2009

Linking CD38 Cell Surface Expression to the Unique Calcium Flux Properties in Human Peripheral B Lymphocytes Following anti-IgM and anti-IgG Stimulation.

Journal of immunology research·2026

Persistent CD8+ T-cell activation (HLA-DR/CD38) as an immunological marker in antiretroviral-treated human immunodeficiency virus-1 patients: A cross-sectional study.

The Journal of international medical research·2026

Serological Detection of Antibodies Against Mycoplasma bovis Infection by Competitive Enzyme-Linked Immunosorbent Assay (cELISA).

Veterinary sciences·2026

Sample Source and Cryopreservation Affect Flow-Cytometric Profiling of Immune-Escape-Related Markers on AML Blasts.

Cancers·2026

Standardising Immunocytochemistry on Breast Cytology: A Formalin Post-Fixation Protocol Achieves High Concordance With Immunohistochemistry for Oestrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2.

Cytopathology : official journal of the British Society for Clinical Cytology·2026

Neutrophil-to-lymphocyte ratio as a gene-specific biomarker of JAK2-driven inflammation across CHIP and myeloproliferative neoplasms.

Frontiers in oncology·2026

Related Experiment Videos

Activity of alpha-interferons in chronic myelogenous leukaemia

Related Concept Videos

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.

Chronic Myeloid Leukemia: Current Guidelines for Diagnosis and Management.

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

Treatment of dyslipidaemias with fluvastatin.

Lipoprotein(a) as a marker for coronary heart disease.

Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial.

Risk factor management: the cardiologist's perspective.

Fluvastatin in combination with other lipid-lowering agents.

The patient at risk: who should we be treating?

Linking CD38 Cell Surface Expression to the Unique Calcium Flux Properties in Human Peripheral B Lymphocytes Following anti-IgM and anti-IgG Stimulation.

Persistent CD8+ T-cell activation (HLA-DR/CD38) as an immunological marker in antiretroviral-treated human immunodeficiency virus-1 patients: A cross-sectional study.

Serological Detection of Antibodies Against Mycoplasma bovis Infection by Competitive Enzyme-Linked Immunosorbent Assay (cELISA).

Sample Source and Cryopreservation Affect Flow-Cytometric Profiling of Immune-Escape-Related Markers on AML Blasts.

Standardising Immunocytochemistry on Breast Cytology: A Formalin Post-Fixation Protocol Achieves High Concordance With Immunohistochemistry for Oestrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2.

Neutrophil-to-lymphocyte ratio as a gene-specific biomarker of JAK2-driven inflammation across CHIP and myeloproliferative neoplasms.

Related Experiment Videos

Activity of alpha-interferons in chronic myelogenous leukaemia

Related Concept Videos

Related Articles